NASD · Healthcare · Diagnostics & Research · USA
Fulgent Genetics Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.
Fulgent Genetics operates a laboratory services business providing anatomic pathology, precision diagnostics, and biopharmaceutical testing through CLIA-licensed laboratories across the United States, along with a telemedicine platform. The company also develops therapeutic candidates using a nanoencapsulation platform technology for treating various cancers. Customers include insurance payors, institutional clients such as hospitals and medical institutions, and individual patients.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Fulgent Genetics Inc stock.
Overvalued: intrinsic value $16.13 per share, market price $20.62, margin of safety -27.9% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $16.13; the price of $20.62 is 28% above that value.
Leak Score: 19/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
FLGT is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $16.13; the price of $20.62 is 28% above that value.
$16.13 per share (as of the 2026-10-30 close), against a market price of $20.62. That is a margin of safety of -27.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
19 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.